1
|
Ohta T, Uto T, Shoyama Y, Sakyiamah MM, Appiah AA, Tanaka H. In vitro fertilization using sperm activated by ML-2-3 isolated from Morinda lucida Bentham leaves. Reprod Med Biol 2022; 21:e12455. [PMID: 35414765 PMCID: PMC8986972 DOI: 10.1002/rmb2.12455] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Revised: 03/18/2022] [Accepted: 03/18/2022] [Indexed: 11/10/2022] Open
Abstract
Purpose ML-2-3 is a novel tetracyclic iridoid derived from Morinda lucida Bentham leaves. This compound has anti-trypanosomal and anti-leishmanial effects. In this study, the authors investigated effects of ML-2-3 on in vitro fertilization (IVF) rates, motility, and acrosome reaction of the mouse sperm. Methods IVF was performed using sperm from BALB/cByJJcl mice treated with ML-2-3. Computer-assisted sperm analysis (CASA) was performed on the sperm of C57BL/6J mice to investigate sperm motility. The effect of ML-2-3 on the acrosome reaction was examined by observing the fluorescence of sperm labeled with the acrosin-EGFP transgene. Results ML-2-3 improved IVF in BALB/cByJJcl mice with low fertilization rates. The optimum concentration of ML-2-3 in sperm pre-culture medium was 20 µM, and no significant toxicity of ML-2-3 was observed in developing embryos at this concentration. ML-2-3 affected sperm motility but not the acrosome reaction. ML-2-3 increased the IVF rate of mouse sperm that had been refrigerated for 3 days. Conclusions ML-2-3 can improve the outcome of IVF and motility without inducing the acrosome reaction in mice. These effects of ML-2-3 on sperm behaviors are different from those of the similar drugs.
Collapse
Affiliation(s)
- Tomoe Ohta
- Department of PharmacognosyFaculty of Pharmaceutical SciencesNagasaki International UniversityNagasakiJapan
| | - Takuhiro Uto
- Department of PharmacognosyFaculty of Pharmaceutical SciencesNagasaki International UniversityNagasakiJapan
| | - Yukihiro Shoyama
- Department of PharmacognosyFaculty of Pharmaceutical SciencesNagasaki International UniversityNagasakiJapan
| | | | | | - Hiromitsu Tanaka
- Lab of Molecular BiologyFaculty of Pharmaceutical SciencesNagasaki International UniversityNagasakiJapan
| |
Collapse
|
2
|
Hashim Y, Toume K, Mizukami S, Ge YW, Taniguchi M, Teklemichael AA, Huy NT, Bodi JM, Hirayama K, Komatsu K. Phenylpropanoid conjugated iridoids with anti-malarial activity from the leaves of Morinda morindoides. J Nat Med 2021; 75:915-925. [PMID: 34189715 DOI: 10.1007/s11418-021-01541-x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2021] [Accepted: 06/11/2021] [Indexed: 12/21/2022]
Abstract
Two phenylpropanoid-conjugated iridoids, deglucosyl gaertneroside (1) and morindoidin (2), were isolated from the leaves of Morinda morindoides (Rubiaceae) by activity-guided fractionation using an anti-malarial activity assay. The known related iridoids molucidin (3) and prismatomerin (4), two lignans, abscisic acid, two megastigmanes, and two flavonol glycosides were also identified. The structures of isolated compounds were elucidated using spectroscopic analysis. The isolated compounds were evaluated for anti-malarial activity against the chloroquine/mefloquine-sensitive strains of Plasmodium falciparum together with cytotoxicity against adult mouse brain cells. Potent anti-malarial activity of 3 and 4 (IC50 of 0.96 and 0.80 μM, CC50 of 1.02 and 0.88 μM, and SI of 1.06 and 1.10, respectively) was shown, while new iridoids 1 and 2 and pinoresinol (5) displayed moderate activity (IC50 of 40.9, 20.6, and 24.2 μM) without cytotoxicity (CC50 > 50 μM). These results indicate that 1-5 may be promising lead compounds for anti-malarial drugs. In addition, our results imply the necessity of the quality control of the extract of M. morindoides leaves based on the contents of 1-5 in terms of the safety and efficacy.
Collapse
Affiliation(s)
- Yasinjan Hashim
- Section of Pharmacognosy, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan
| | - Kazufumi Toume
- Section of Pharmacognosy, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.
| | - Shusaku Mizukami
- Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.,Department of Clinical Product Development, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.,Department of Immune Regulation, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan
| | - Yue-Wei Ge
- Section of Pharmacognosy, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan
| | - Mayumi Taniguchi
- Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.,Department of Immune Regulation, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan
| | - Awet Alem Teklemichael
- Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.,Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan
| | - Nguyen Tien Huy
- Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.,Department of Clinical Product Development, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.,School of Tropical Medicine and Global Health, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan
| | - Joseph M Bodi
- Department of Pediatrics, Emergency and Intensive Care Unit, University Hospital of Kinshasa, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo
| | - Kenji Hirayama
- Department of Immunogenetics, Institute of Tropical Medicine (NEKKEN), Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.,Graduate School of Biomedical Sciences, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan.,School of Tropical Medicine and Global Health, Nagasaki University, 1-12-4 Sakamoto, Nagasaki, 852-8523, Japan
| | - Katsuko Komatsu
- Section of Pharmacognosy, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan.
| |
Collapse
|